tianqing Chu

Dr. tianqing Chu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2020 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HQHuiping Qiang
Huiping Qiang
QCQing Chang
Qing Chang
JXJianlin Xu
Jianlin Xu
JQJialin Qian
Jialin Qian
YZYanwei Zhang
Yanwei Zhang
TCtianqing Chu
tianqing Chu

1 January 2022 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
HQHuiping Qiang
Huiping Qiang
YLYuqiong Lei
Yuqiong Lei
YSYinchen Shen
Yinchen Shen
JLJiaqi Li
Jiaqi Li
HZHua Zhong
Hua Zhong
TCtianqing Chu
tianqing Chu
Background: The incidence of bone metastases in non-small cell lung cancer (NSCLC) patients is about 30–40% and bone-related events can seriously affect quality of life. Immune checkpoint inhibitor (ICI) therapy has become the standard treatment for advanced NSCLC patients. However, the specific efficacy of ICIs in NSCLC patients with bone metastases remains unclear. The aim of the present study was to explore the prognosis of immunotherapy in this population and to find potential biomarkers. Methods: In this retrospective study, a total of 110 advanced NSCLC patients with bone metastases who received pembrolizumab therapy were enrolled. Patient characteristics; palliative bone radiotherapy or bone-targeted therapy; serum levels of lactate dehydrogenase (LDH), and the neutrophil-to-lymphocyte ratio (NLR) at baseline were assessed. The correlation of these factors with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) was analyzed. Results: The ORR of the total population was 29.1%, and PFS and OS were 7.0 and 14.8 months, respectively. Fifty-eight patients (52.7%) received pembrolizumab treatment as first-line therapy, and 52 patients (47.3%) as second-line therapy or beyond [ORR: 41.4% vs. 15.4%, P=0.011; PFS: 9.0 vs. 4.0 months, P=0.004; OS: not reached (NR) vs. 11.5 months, P<0.0001]. Bone therapy, including palliative bone radiotherapy and bone-targeted therapy, increased the ORR (34.9% vs. 11.1%, P<0.0001) and prolonged PFS (8.5 vs. 2.0 months, P=0.002). Eastern Cooperative Oncology Group performance status score of 0–1 [OS: hazard ratio (HR) =0.117, P<0.0001] and first-line pembrolizumab therapy (OS: HR =0.372, P=0.004) were independent predictors of OS. Patients whose baseline serum LDH level was ≤240.5 IU/L (NR vs. 10.0 months, P<0.0001) or NLR ≤5.55 (NR vs. 18.0 months, P=0.039) showed longer OS. Conclusions: The efficacy of Pembrolizumab therapy is confirmed in advanced NSCLC patients with bone metastases, particularly when palliative bone radiotherapy or bone-targeted therapy is delivered. Baseline serum LDH level ≤240.5 IU/L and NLR ≤5.55 might predict the prognosis of patients with bone metastases from advanced NSCLC treated with immunotherapy.

7 November 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
XCXiangling Chu
Xiangling Chu
HQHuiping Qiang
Huiping Qiang
MXMengqing Xie
Mengqing Xie
XLXing Li
Xing Li
JZJing Zhao
Jing Zhao
CSChunxia Su
Chunxia Su

1 September 2021 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
XYXin Yu
Xin Yu
JLJiaqi Li
Jiaqi Li
LYLingyun Ye
Lingyun Ye
JZJing Zhao
Jing Zhao
MXMengqing Xie
Mengqing Xie
CSChunxia Su
Chunxia Su
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy Xin Yu, Jiaqi Li, Lingyun Ye, Jing Zhao, Mengqing Xie, Juan Zhou, Yinchen Shen, Fei Zhou, Yan Wu, Chaonan Han, Jialin Qian, Tianqing Chu, Chunxia Su

2 April 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
QCQing Chang
Qing Chang
HQHuiping Qiang
Huiping Qiang
JQJialin Qian
Jialin Qian
YLYuqiong Lei
Yuqiong Lei
JLJiahuan Lu
Jiahuan Lu
TCtianqing Chu
tianqing Chu
Background: The frequency of epidermal growth factor receptor (EGFR) mutations and the efficacy of tyrosine kinase inhibitor (TKI) in Chinese female patients with lung squamous cell carcinoma (SCC) are unknown. This study was designed to investigate the incidence of EGFR mutations and the role of targeted therapy in advanced Chinese female lung SCC patients.Methods: Advanced female patients diagnosed with lung SCC at the Shanghai Chest Hospital between January 2013 and December 2018 were retrospectively analyzed.Results: A total of 4223 advanced lung SCC patients were screened, and there were 154 female lung SCC patients who had underwent EGFR mutation detection. Positive EGFR mutations were found in 29.9% (46/154) of female lung SCC patients, including twenty-three 19del mutation (14.9%), twenty-one 21L858R mutation (13.6%) and other mutations (1.4%, 21861Q and 20ins). For 45 EGFR positive mutation female SCC patients, the median progression-free survival (PFS) of patients who received EGFR-TKI therapy (n=38) was 8.0 months (95% CI, 5.4-10.7 months), which was significantly longer than patients who were treated with chemotherapy (8.0 vs. 3.2 months, p=0.024), and the median overall survival (OS) was also longer (24.9 months vs. 13.9 months, p=0.020). The objective response rate (ORR) was 44.7% (17/38), and the disease control rate (DCR) was 81.6% (31/38). For 105 female SCC patients with EGFR negative mutation, the median OS was 18.6 months (95% CI, 14.2-22.9 months) and it was no different from that of EGFR positive mutation patients (18.6 vs. 22.8 months, p=0.377).Conclusion: For advanced Chinese female lung SCC patients with EGFR positive mutations, targeted therapy could confer longer PFS and OS than chemotherapy, but the survival was similar with patients who were negative EGFR mutations.

8 February 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
HQHuiping Qiang
Huiping Qiang
JLJiaqi Li
Jiaqi Li
QCQing Chang
Qing Chang
YSYinchen Shen
Yinchen Shen
JQJialin Qian
Jialin Qian
TCtianqing Chu
tianqing Chu
Background: Chemotherapy is the main treatment for patients with lung squamous cell carcinoma (LUSC). However, how chemotherapy affects their immune system is rarely reported. This study was aimed to compare the differences in the immune microenvironment of LUSC patients with or without chemotherapy.Methods: A total of 494 LUSC samples were obtained from The Cancer Genome Atlas (TCGA) database. The immune cell infiltration was evaluated by the ssGSEA algorithm, and the tumor subtype was assayed by ConsensusClusterPlus. The differences in tumor mutation burden (TMB) and clinical information between the two types were then compared. Additionally, the differentially expressed genes (DEGs) between two types were analyzed and hub genes were validated in the GEO database.Results: LSCC samples in TCGA were divided into three subtypes. Then, combining the tumor subtype and immune scores, the samples were divided into hot and cold tumors. Regardless of whether LUSC patients received chemotherapy, the survival of the hot tumor group was not significantly prolonged compared with that of the cold tumor group. For LUSC patients who received chemotherapy, the TMB value in hot tumor group was significantly higher. Total 501 DEGs were identified between two groups. The high expressions of hub genes CD19, CTLA4, FCGR3B, CD80, IL-10, etc. were also validated in the GSE37745 dataset.Conclusion: Chemotherapy does not affect the survival and prognosis of LUSC patients, but it significantly increases the TMB value of patients with hot tumor. The DEGs, especially hub genes, such as CD19, CTLA4, and FCGR3B, may serve as biomarkers to distinguish cold and hot tumors in LUSC.